1.1. Aims and Objectives
The European Association of Urology (EAU) Sexual and Reproductive Health Guidelines aim to provide a comprehensive overview of the medical aspects relating to sexual and reproductive health in adult men. These Guidelines cover the former EAU Guidelines on Male Sexual Dysfunction, Male Infertility and Male Hypogonadism.
It must be emphasised that guidelines present the best evidence available to the experts. However, following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - while taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.
1.2. Panel Composition
The EAU Sexual and Reproductive Health Guidelines Panel consists of an international multi-disciplinary group of urologists, endocrinologists and a psychologist. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website:
1.3. Available Publications
A quick reference document, the Pocket Guidelines, is available. This is an abridged versions that may require consultation together with the full text version. A number of scientific publications are also available. All documents can be viewed through the EAU website: http://www.uroweb.org/guideline/sexual-and-reproductive-health/.
1.4. Publication History
The EAU Sexual and Reproductive Health Guidelines were first published in 2020. This 2023 document presents a limited update of the 2022 publication with the edition of a new section on penile size abnormalities and dysmorphophobia.
1.5. Changes in the Guideline for 2023
Key changes in the 2023 publication include:
- Section 3.7.9 - New recommendations on clinical and biochemical follow up during testosterone therapy.
- Section 18.104.22.168 – Regeneration therapies for the treatment of erectile dysfunction.
- Section 22.214.171.124.1 – Botulinum Neurotoxin for the treatment of erectile dysfunction.
- Section 9 - Addition of a new guidelines section on penile size abnormalities and dysmorphophobia.
- Section 10.1.2.5 – New recommendation related to the diagnosis of ischaemic priapism.